We compared the efficacy of a 400-mg once-weekly dosage versus a 200-mg daily dosage of fluconazole for the prevention of deep fungal infections in a multicenter, randomized, doubleblind trial of 636 human immunodeficiency virus -infected patients to determine if a less intensive fluconazole regimen could prevent these serious but relatively infrequent complications of AIDS. In the intent-to-treat analysis, a deep fungal infection developed in 17 subjects (5.5%) randomly assigned to daily fluconazole treatment and in 24 (7.7%) given weekly fluconazole during 74 weeks of follow-up (risk difference, 2.2%; 95% confidence interval [CI], 01.7% to 6.1%). Thrush occurred twice as frequently in the weekly versus daily fluconazole recipients (hazard ratio, 0.59; 95% CI, 0.40 -0.89), and in a subset of patients evaluated, fluconazole resistance was infrequent. Fluconazole administered once weekly is effective in reducing deep fungal infections in patients with AIDS, but this dosage is less effective than the 200-mg-daily dosage in preventing thrush.
Fungal infections complicating the course of persons instudy of HIV-infected individuals with õ200 CD4 cells/mm 3 , 11,756 doses of fluconazole were given for each case of serious fected with HIV cause a broad spectrum of diseases, ranging from asymptomatic mucocutaneous candidiasis to life-threatenfungal infection prevented [7] . Costs associated with fungal prophylaxis are appreciable; Freedberg et al. estimated costs ing cryptococcal meningitis. Fluconazole is effective in preventing thrush, but primary prophylaxis is not routinely utilized at $100,000 per quality life-year saved [8] . because of concern about promoting fluconazole resistance among Candida strains causing this otherwise easily treated See editorial response by Mylonakis and Flanigan infection [1 -3] . Fluconazole also prevents the most common on pages 1376 -8. serious mycosis, disseminated cryptococcal infection, but is recommended only for secondary prophylaxis or maintenance therapy because of the relatively low risk of primary infection, Substantially reducing the dose of fluconazole would lower even in patients with severe immunosuppression [3 -6] . In one overall costs of deep fungal prophylaxis but would be reasonable only if efficacy were preserved and fluconazole resistance among Candida and Cryptococcus strains did not increase. Intermittent fluconazole therapy has been associated with a laxis against disseminated Mycobacterium avium complex lates for which MICs were £8 mg/mL were interpreted as fluconazole-susceptible [13] . Patients developing deep fungal (MAC) infection [11] .
infections discontinued receiving the study medications and were followed for survival data. Adherence to therapy was Methods measured by pill counts when participants returned their studymedication packets at each visit.
Study Design and Patient Population
This double-blind, randomized, multicenter trial compared Endpoints weekly to daily fluconazole treatment for the prevention of fungal infections in persons with HIV infection and õ100 CD4 The primary endpoint of the study was diagnosis of a deep fungal infection. Cryptococcal disease was defined by a Cryptocells/mm 3 . Persons were randomly assigned to receive 400 mg once per week or 200 mg per day, a fluconazole dosage coccus neoformans -positive culture of blood, spinal fluid, urine, or other sterile-site specimen or by two consecutive demonstrated to prevent superficial and deep fungal infections in the AIDS Clinical Trials Group (ACTG) 981 study [7] . cryptococcal antigen titers (in blood or spinal fluid) of ú1:8.
Candidal esophagitis was classified either as definite (biopsySubjects in this study represented 94% of patients co-enrolled in the CCTG trial of prophylaxis for MAC infection [11] . All proven) or probable (on the basis of clinical symptoms and response to antifungal therapy). Candidemia, coccidioimycosis, subjects were independently randomized to receive azithromycin (1,200 mg weekly), rifabutin (300 mg daily), or both as histoplasmosis, and blastomycosis documented by a positive culture of a specimen from an infected site or a biopsy sample prophylaxis for MAC infection, and none of the subjects had disseminated MAC infection or signs or symptoms suggestive were study endpoints. Primary endpoints were reviewed by the protocol chairpersons and CCTG study investigators without of MAC infection at enrollment.
Inclusion criteria for the study were documented HIV infecknowledge of treatment assignment. Secondary endpoints included fluconazole toxicity, survival, and mucocutaneous cantion, a CD4 cell count of õ100/mm 3 , an absolute neutrophil count of §500/mm 3 , a platelet count of §50,000/mm 3 , a bilirudidiasis, defined as a compatible clinical picture with either evidence of candidal organisms on microscopic examination bin level õ3 times the upper limit of normal, a hepatic transaminase level õ5 times the upper limit of normal, and a creatinine of a potassium hydroxide preparation or a culture yielding Candida species. level õ3 times the upper limit of normal. Patients were excluded for active fungal infections (cryptococcosis, histoplasmosis, blastomycosis, aspergillosis, mucocutaneous candidia-
Statistical Analysis
sis, or aspergillosis) or ongoing chronic therapy with any systemic antifungal agent (fluconazole, ketoconazole, itraconaBecause we regarded a doubling of incidence with weekly prophylaxis to be unacceptable, the sample size was selected to zole, or amphotericin B). Patients with odynophagia were eligible only after candidal esophagitis had been excluded. provide 80% power to detect an increase in the incidence of deep fungal infections from 5% to 10% at the 0.05 level of significance. Subjects who had had prior episodes of mucocutaneous candidal infections could participate even if they were receiving Crude risks, failure rates, and risk differences were calculated and compared with use of standard methods. The Kaplan-Meier daily fluconazole at study enrollment, if they discontinued receiving open-label fluconazole. Pregnant and nursing females method was used to estimate the cumulative risk of developing a deep fungal infection and to estimate the risk of developing were not allowed to enroll in the study. Approval of institutional review boards and informed consent were required before secondary endpoints of thrush, toxicity, and survival. Cox proportional-hazards models, stratified by study site and M. avium comstudy enrollment.
Patients were assessed monthly for evidence of fungal infecplex prophylaxis and adjusted for baseline CD4 cell count, were used to calculate hazard ratios for the primary and secondary tion or drug toxicity and underwent bimonthly laboratory evaluations consisting of complete blood cell counts and liver funcendpoints. All statistical tests were two-tailed.
Both an intent-to-treat analysis and an on-treatment analysis tion tests. Patients developing mucocutaneous candidiasis were treated with topical agents (clotrimazole or nystatin) while adwere used to compare efficacy of the two prophylactic strategies.
The intent-to-treat analysis compared all events developing during ministration of the study medication was continued. For those who failed to respond to topical agents, the study drug dosing the entire study period between the two arms, according to the initial assignments at randomization. In the on-treatment analysis, was interrupted and treatment with systemic antifungal agents was instituted at the discretion of their primary physician.
events occurring within 30 days of initiation of prophylaxis, ú30 days after permanent discontinuation of study treatment, or after Isolates from breakthrough mucosal infections were shipped to a central laboratory for susceptibility testing by means of 30 days of interrupted therapy because of the need for disallowed medications were not considered prophylaxis failures and were macro-broth dilution [12] . Candidal isolates for which MICs were §64 mg/mL were defined as fluconazole-resistant; isoexcluded as study endpoints.
/ 9c5c$$DE09 of 528 and 502 days, respectively. The baseline characteristics of 636 patients who were randomized and received fluconazole prophylaxis in the two study arms were similar (table 1). The median CD4 cell counts were serious fungal infection in the intent-to-treat analysis (table 2) . 41/mm 3 and 40/mm 3 in the daily and weekly fluconazole arms, The risk difference between the two arms, 2.2%, had a 95% respectively. Sixty-two percent of patients had a history of confidence interval of 01.7% to 6.1%. Candidal esophagitis thrush. Forty-two percent of patients had used fluconazole bewas the most frequent serious fungal infection, occurring in 12 fore enrollment in the study, and the median durations of prior subjects (3.9%) randomized to receive daily fluconazole and fluconazole exposure for these patients were 2 months (daily 15 subjects (4.8%) randomized to receive weekly fluconazole fluconazole) and 4 months (weekly fluconazole).
(risk difference, 0.9%; 95% CI, 02.2% to 4.2%; P Å .56).
Cryptococcal disease developed in 7 subjects, of whom 2 were randomized to daily and 5 to weekly fluconazole (risk Å 0.6%
Deep Fungal Infections and 1.6%, respectively; risk difference, 1.0%; 95% CI, 00.7% to 2.6%; P Å .25). Seventeen subjects (5.5%) receiving daily fluconazole and Candidemia and histoplasmosis were rare events, oc-24 subjects (7.7%) receiving weekly fluconazole developed a curring in three and four subjects, respectively. Seventeen deep fungal infections were included in the on-treatment analysis. Candidal esophagitis was the most common occurrence: four cases occurred with daily fluconazole and seven developed in subjects who reported compliance with weekly fluconazole prophylaxis.
Daily fluconazole Weekly fluconazole
The time to onset of deep fungal infection was similar in Characteristic (n Å 318) (n Å 318) the two prophylaxis groups ( figure 1A ). In the Cox regres- Rates of deep fungal infection were also determined ac- 
Superficial Fungal Infections
differ among patients assigned to the three prophylactic regimens for MAC infection. Overall rates of deep fungal infection Thirty-nine subjects (12.3%) receiving daily fluconazole and were 7.7%, 5.2%, and 6.9% in the azithromycin, rifabutin, and 63 subjects (19.9%) receiving weekly fluconazole developed thrush (risk difference, 7.5%; 95% CI, 01.8 to 13.2; P Å .01). combination arms, respectively.
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In the Cox regression model, the hazard ratio for the risk of tients receiving daily and 37.2% receiving weekly fluconazole died during the course of the study. thrush was 0.59 (95% CI, 0.40 -0.89; P Å .011), favoring daily fluconazole. The time to onset of an initial episode of thrush was significantly shorter in patients receiving weekly vs. daily fluconazole in the Kaplan-Meier analysis (figure 1B). Six Discussion (1.9%) of the subjects receiving daily fluconazole and 23 (7.3%) receiving weekly fluconazole had more than one epi-
The protection against serious fungal infection afforded by weekly and daily prophylaxis was similar over nearly 600 pasode of thrush. Rates of thrush were 16.8 per 100 patient-years among patients receiving daily fluconazole and 35.7 per 100 tient-years of follow-up. This study complements previous work showing that the 200-mg-daily dosage of fluconazole was patient-years among patients receiving weekly fluconazole (rate difference, 18.9 per 100 patient-years; 95% CI, 10.5 -27.2 [per effective in reducing the rate of serious fungal infections in HIV-infected patients with significant immunosuppression [7] . 100 patient-years]; P õ .001).
Isolates from 26 (25.5%) of all culture-confirmed thrush Furthermore, we found that intermittent fluconazole dosing was not associated with occurrence of candidal infections refractory episodes were tested for susceptibility to fluconazole at the central laboratory. Although requested, isolates from the other to azole therapy. We observed a 2.2% difference in risk of serious fungal 74.5% of cases were not sent to the central laboratory. Resistance, defined as an MIC of ú64 mg/mL, was noted in 1 of 8 infections between the prophylaxis groups, indicating that one would need to treat 45 patients with 10,961 capsules for each isolates from subjects receiving daily fluconazole and 1 of 18 isolates from subjects receiving weekly fluconazole; 5 (63%) additional case prevented by daily rather than weekly dosing. The upper limit of the 95% confidence intervals for the protecof the 8 Candida isolates from the daily arm and 14 (78%) of the 18 from the weekly arm were fluconazole-susceptible (MIC, tion afforded by daily compared to weekly dosing was 6%, while the upper limit for the risk of serious fungal infection in £8 mg/mL). Only one non-albicans Candida isolate (Candida krusei) was identified, against which the MIC of fluconazole those randomized to weekly treatment was 12%. This implies that if we conducted the trial repeatedly, the difference in prowas 8 mg/mL; it was recovered from a subject receiving daily fluconazole. Two patients were treated with intravenous amtection would be no greater than 6% and the absolute risk of serious infection with weekly dosing would be no greater than photericin B for thrush.
Dermatophyte infections were diagnosed on the basis of clin-12% in 95% of repetitions. The results of this study can be best appreciated in perspecical findings and were significantly less frequent in subjects receiving daily vs. weekly fluconazole. Forty-nine subjects tive with the smaller but longer ACTG 981 study. That study, which compared topical therapy with clotrimazole troches to (15.5%) randomized to the weekly fluconazole regimen developed a dermatophyte infection, compared with 30 subjects systemic fluconazole at a dosage of 200 mg daily, enrolled 205 subjects with õ100 CD4 cells/mm 3 at enrollment. The 12-(9.5%) randomized to the daily dosing regimen (RR, 0.61; 95% CI, 0.40 -0.94). month cumulative failure rates for serious fungal infections were 15.5% for those randomized to clotrimazole but only 2.0% for those randomized to fluconazole (authors' unpub-
Adverse Events and Survival
lished data). Furthermore, the upper limit of the 95% confidence interval for the 12-month cumulative risk of disease in the The most frequently reported adverse events during the study were gastrointestinal symptoms, occurring in 72.6% of subjects ACTG 981 fluconazole group, 7.7%, included the observed risk of disease in this study (5.5%). Thus, the similarity between receiving daily fluconazole and 70.4% of subjects receiving weekly fluconazole. Diarrhea (48%) and nausea (33%) that failure rates in the two arms of our study was not likely caused by a spuriously high rate in the daily fluconazole arm. were mild to moderate in severity were common but seldom necessitated discontinuation of medication. Fluconazole treat-
The potency of fluconazole in this trial for preventing cryptococcal disease in severely immunocompromised patients was ment was discontinued because of gastrointestinal symptoms for 6.3% of patients receiving weekly fluconazole and 6.9% of striking. In the on-treatment analysis, which included only events involving those subjects without significant interruptions subjects receiving daily fluconazole. Fluconazole was withdrawn because of laboratory abnormalities (increase in liver (for ú30 days) of fluconazole prophylaxis, there were only two cases of cryptococcal meningitis among 280 subjects. This function test values or hematologic abnormalities) in 3.1% of patients receiving daily and 2.5% of patients receiving weekly observation suggests that weekly fluconazole is sufficient to inhibit C. neoformans replication and subsequent disseminated fluconazole. The groups were also similar in the Cox regression analysis in terms of time to withdrawal because of drug toxicity infection in most subjects. Observations that once-weekly, thrice-weekly, or even any reported use of fluconazole treat-(hazard ratio, 1.15; 95% CI, 0.74 -1.77).
Survival did not differ between the two fungal prophylaxis ment is associated with a reduction in cryptococcal disease are consistent with this finding [5, 9, 10] . groups (hazard ratio, 0.98; 95% CI, 0.76 -1.26); 36.7% of pa-/ 9c5c$$DE09 11-13-98 16:05:53 cidas UC: CID Once-weekly fluconazole was relatively less successful than cause optimal long-term benefit requires frequent administration of multiple agents. Because patients are less likely to daily dosing in preventing thrush. Although prior placebocontrolled studies have established the efficacy of weekly dosadhere to more complicated drug regimens, simplification of prophylactic regimens represents a high priority in the manageing of fluconazole for oral and vaginal candidiasis, the results of this study are not surprising, given that patients in this study ment of HIV-infected patients. Recently published guidelines for the prevention of opportuhad greater immune suppression [14 -16] . A dosing frequency between daily and weekly (e.g., three times weekly) may pronistic infections in HIV-infected persons did not recommend fluconazole as primary prophylaxis for cryptococcal disease vide the optimal cost-benefit ratio for protection against thrush, and a clinical trial is currently under way to address this because of the low incidence of disease, absence of survival benefit, potential for drug interactions, risk of selection of resisquestion.
In addition to cost, the potential for selection of fluconazoletant Candida strains, and increased cost [27] . Our data do not contradict these recommendations. Rather, this study provides resistant organisms has been a major argument against the universal use of fluconazole prophylaxis by patients with AIDS.
additional information about the outcome of a daily versus weekly regimen for clinicians choosing to prescribe fluconazole Thrush refractory to azole therapy is caused by selection of either C. albicans resistant to fluconazole or non-albicans Canprophylaxis. While efficacy is modestly reduced, the costs of prophylaxis can be reduced by more than two-thirds with use dida species that are inherently more azole-resistant [17 -19] . Cross-resistance to other oral azoles is common and may necesof weekly dosing, and resistance is not increased. These factors should be considered by clinicians selecting prophylactic regisitate treatment with intravenous amphotericin B, which is more toxic [20] .
mens for their patients. Risk factors for the development of fluconazole resistance include immunosuppression, prior opportunistic infections, and
